文献速递其他结缔组织病

幼年型肌炎中抗FHL1自身抗体与抗Ro52自身抗体相关但不与严重疾病特征相关

Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

研究在北美338例幼年特发性炎症性肌病患者和91例幼年健康对照中采用ELISA筛查抗FHL1自身抗体,发现10.9%患者和1.1%对照阳性;抗FHL1抗体与肌炎相关自身抗体(OR 2.09)及抗Ro52抗体(OR 4.17)、V征皮疹(OR 2.59)相关,但未发现其他疾病严重程度特征或标志物差异,与成人IIM不同。

要点

  • 抗FHL1自身抗体见于10.9%幼年IIM患者和1.1%健康对照。
  • 抗FHL1抗体与肌炎相关自身抗体(OR 2.09)、抗Ro52抗体(OR 4.17)和V征皮疹(OR 2.59)相关。
  • 与成人IIM不同,幼年肌炎中抗FHL1抗体未与其他独特临床特征或更差结局相关。

核心结论

  • 抗FHL1自身抗体见于约11%的幼年IIM患者,常与肌炎相关自身抗体包括抗Ro52抗体共存。
  • 与成人IIM不同,幼年肌炎中抗FHL1自身抗体与V征皮疹相关,但不与其他独特临床特征或更差结局相关。

研究设计与样本

  • 研究纳入北美338例幼年IIM患者和91例幼年健康对照,采用ELISA筛查抗FHL1自身抗体。
  • 在幼年IIM患者中比较有无抗FHL1自身抗体者的临床特征和HLA等位基因。

主要发现

  • 抗FHL1自身抗体在10.9%的幼年IIM患者和1.1%的对照中阳性。
  • 抗FHL1自身抗体在临床和血清学亚组间的频率无差异。
  • 亚裔患者中抗FHL1自身抗体比例更高(11% vs 0.7%;P = 0.002)。
  • 肌炎相关自身抗体(OR 2.09,CI 1.03,4.32)、抗Ro52自身抗体(OR 4.17,CI 1.83,9.37)和V征皮疹(OR 2.59,CI 1.22,5.40)与抗FHL1自身抗体相关。
  • 其他特征或疾病严重程度标志物无差异,白人肌炎患者中未发现抗FHL1自身抗体与HLA的关联。

关键数值与推荐

  • 抗FHL1自身抗体阳性率:幼年IIM患者10.9%,健康对照1.1%。
  • 肌炎相关自身抗体与抗FHL1自身抗体相关:OR 2.09(CI 1.03,4.32)。
  • 抗Ro52自身抗体与抗FHL1自身抗体相关:OR 4.17(CI 1.83,9.37)。
  • V征皮疹与抗FHL1自身抗体相关:OR 2.59(CI 1.22,5.40)。
  • 亚裔患者抗FHL1自身抗体比例:11% vs 0.7%;P = 0.002。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Four-and-a-half LIM domains 1 (FHL1) is a muscle-specific protein. Autoantibodies against FHL1 were recently discovered in adults with idiopathic inflammatory myopathies (IIMs) and were found to be associated with clinical features and outcomes indicative of increased disease severity. Anti-FHL1 autoantibodies have not been described in children. Here, the prevalence and clinical features associated with anti-FHL1 autoantibodies were examined in a large North American cohort of juvenile patients with IIM. METHODS: Sera from 338 juvenile IIM patients and 91 juvenile healthy controls were screened for anti-FHL1 autoantibodies by ELISA. Clinical characteristics and HLA alleles of those with and without anti-FHL1 autoantibodies were compared among those with juvenile IIM. RESULTS: Anti-FHL1 autoantibodies were present in 10.9% of juvenile IIM patients and 1.1% of controls. The frequency of anti-FHL1 autoantibodies among clinical and serologic subgroups did not differ. A higher percentage of Asian patients had anti-FHL1 autoantibodies (11% vs 0.7%; P = 0.002). Myositis-associated autoantibodies (MAAs) [odds ratio (OR) 2.09 (CI 1.03, 4.32)], anti-Ro52 autoantibodies specifically [OR 4.17 (CI 1.83, 9.37)] and V-sign rash [OR 2.59 (CI 1.22, 5.40)] were associated with anti-FHL1 autoantibodies. There were no differences in other features or markers of disease severity. No HLA associations with anti-FHL1 autoantibodies in Caucasian myositis patients were identified. CONCLUSION: Anti-FHL1 autoantibodies are present in ∼11% of juvenile IIM patients and commonly co-occur with MAAs, including anti-Ro52 autoantibodies. In contrast to adult IIM, anti-FHL1 autoantibodies in juvenile myositis are associated with V-sign rash but not with other distinctive clinical features or worse outcomes.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Sherman MA, Graf R, Sabbagh SE, et al. Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features. Rheumatology (Oxford). 2023. PMID: 35961028. doi:10.1093/rheumatology/keac428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。